I expect ZD's $18.29 EPS at a 3.16 multiple to offer the book's deepest reported earnings discount. The 2.25% twenty-session decline does not settle whether that denominator is repeatable.

What would change the view: I'm wrong if later filings expose one-off profits or weak cash realization; missing reconciliation keeps even this largest part of the portfolio below 5%.

I expect ASO's $5.87 EPS at 9.35 times earnings to provide a useful valuation cushion. The 8.84% twenty-session gain supplies secondary confirmation without replacing the profit ledger.

What would change the view: I'm wrong if subsequent reports reveal deteriorating earnings or inventory-related cash pressure; I hold the part of the portfolio at 4%, not the maximum.

I expect INSW's $14.33 EPS at 8.73 times earnings to support continued value realization. October 13 commentary reports $935 million liquidity alongside $244 million carrier orders, a useful funding cross-check.

What would change the view: I'm wrong if commitments consume liquidity faster than operations replenish it; trailing distributions are not a perpetual coupon.

I expect PARR's $16.78 EPS at only 5.36 times earnings to leave substantial room for value realization. Its 7.51% twenty-session advance corroborates the ledger without proving earnings quality.

What would change the view: I'm wrong if later filings expose transient profits or cash-conversion weakness; projected growth headlines do not justify breaching my position cap.

I expect TDC's $4.46 EPS at 6.83 times earnings to provide room for a valuation recovery. Its 3.71% twenty-session advance gives restrained confirmation rather than a momentum mandate.

What would change the view: I'm wrong if subsequent filings reveal nonrecurring earnings or deteriorating cash conversion; the low multiple earns attention, not immunity from accounting scrutiny.

I expect LPG's $7.55 EPS at a 7.68 multiple to support earnings-backed appreciation. Four recorded payments produce a 5.78% trailing yield, a cash trail rather than a forward commitment.

What would change the view: I'm wrong if later statements show shrinking profits or distributions unsupported by cash; I retain a sub-4% part of the portfolio.

I expect LRN's $7.47 EPS at 11.11 times earnings to support patient appreciation. That fundamental file is dated April 29, so October's nearly flat twenty-session return cannot refresh its accounting substance.

What would change the view: I'm wrong if newer filings undermine the profit base; I retain exposure without awarding stale earnings a larger part of the portfolio.

I expect ABCB's $5.54 of reported EPS at 14.25 times earnings to support measured appreciation. The 1.01% dividend supplies a separate cash receipt, not a loan-quality certificate.

What would change the view: I'm wrong if subsequent disclosures reveal credit costs consuming the earnings base; absent that ledger detail, I keep sizing restrained.

I expect ABG's 5.24 multiple on $31.40 of EPS to leave room for earnings-led recovery. The 19.80% twenty-session decline is an unresolved clue, not a bargain certificate.

What would change the view: I'm wrong if later filings show those profits cannot recur; I retain a contained part of the portfolio rather than average down aggressively.

I expect ACA's $10.14 EPS at a 14.52 multiple to provide a workable foundation for patient appreciation. Its 1.45% twenty-session gain is quiet corroboration, not the substance of my case.

What would change the view: I'm wrong if subsequent filings expose nonrecurring profits or weaker cash conversion beneath that reported earnings line.

I expect CACC to recover value if $41.91 of reported EPS remains durable at a 13.03 multiple. Its 9.02% twenty-session decline argues against enlarging this credit file.

What would change the view: I'm wrong if collection performance or financing costs undermine those earnings; missing receivables detail prevents a stronger conviction stamp.

I expect ADMA's positive $0.64 EPS at 16.11 times earnings to anchor returns in profits rather than excitement. The 19.74% twenty-session advance confirms interest but earns no larger allocation.

What would change the view: I'm wrong if later statements fail to sustain profitability; this biological-products file stays capped at 3%.

I expect HRMY's $3.38 EPS at a 10.96 multiple to leave room for valuation recovery. The 12.19% twenty-session loss is adverse evidence that keeps this pharmaceutical part of the portfolio capped.

What would change the view: I'm wrong if subsequent filings weaken the recurring profit base; I rely on earnings, not the supplied pipeline headline.

I expect PLAB's $2.16 EPS at 13.48 times earnings to offer a reasonably priced semiconductor profit stream. The 6.82% twenty-session gain supplies secondary confirmation, but not a receivables audit.

What would change the view: I'm wrong if later disclosures show weakening profitability or cash trapped in working capital; I keep the allocation below 3%.

I expect MATX's $13.28 EPS at 17.71 times earnings to support measured compounding. The 1.42% twenty-session decline offers no compelling reason to rewrite the existing part of the portfolio.

What would change the view: I'm wrong if subsequent disclosures show that cash generation cannot sustain reported profits; its higher multiple than the other shipping files limits sizing.

I expect PLMR's $7.06 EPS at an 18.90 multiple to support earnings-backed appreciation. October 13 commentary reports recent earnings beats, useful corroboration but no substitute for reserve scrutiny.

What would change the view: I'm wrong if later filings expose inadequate reserves or weaker recurring profits; I preserve a modest part of the portfolio rather than buy an earnings-surprise prediction.

I expect ABM's $2.88 EPS at 17.60 times earnings to support modest appreciation. But October 13 commentary flags $1.8 billion borrowings and interest expense rising 13.2%. I trim current 2.77% and recent 2.80% intent to 2.60%.

What would change the view: I'm wrong if financing costs overwhelm operating progress.

I expect EPAM's $6.96 EPS at 16.59 times earnings to furnish a foundation for recovery. The 6.49% twenty-session decline keeps my pencil cautious and allocation modest.

What would change the view: I'm wrong if later reports show lasting earnings deterioration rather than temporary price weakness; I will not confuse a falling quote with proof.

I expect AEO's 9.31 multiple on $1.91 EPS to retain some valuation support. October 13 commentary flags quarterly EPS declining 7.55%, despite the strong tape. I preserve the current near-2% part of the portfolio and recent 2% intent.

What would change the view: I'm wrong if earnings erosion strips away the apparent discount.

I expect DXC's 7.83 multiple on $1.63 EPS to support an earnings-led rerating. The 6.06% twenty-session advance is corroboration, not permission to enlarge yesterday's small target.

What would change the view: I'm wrong if later filings reveal that reported profit fails to translate into recurring cash; the position remains a restrained recovery file.

I expect KSS's $2.57 EPS at 8.21 times earnings to retain a modest value opportunity. The 28.97% twenty-session gain is emphatic price confirmation, not evidence that inventory and liabilities are clean.

What would change the view: I'm wrong if subsequent filings show profit deterioration; I keep this fast-moving file at only 1.80%.